Literature DB >> 22398730

Neuroinflammation and common mechanism in Alzheimer's disease and prion amyloidosis: amyloid-associated proteins, neuroinflammation and neurofibrillary degeneration.

Annemieke J M Rozemuller1, Casper Jansen, Anna Carrano, Elise S van Haastert, David Hondius, Saskia M van der Vies, Jeroen J M Hoozemans.   

Abstract

BACKGROUND: In cases with a long (>1 year) clinical duration of prion disease, the prion protein can form amyloid deposits. These cases do not show accumulation of 4-kDa β-amyloid, which is observed in amyloid deposits in Alzheimer's disease (AD). In AD, amyloid is associated with inflammation and neurofibrillary degeneration, and it is elusive whether prion amyloid is associated with these changes as well.
OBJECTIVES: The presence of inflammation and neurofibrillary degeneration was evaluated in prion amyloidosis.
MATERIAL AND METHODS: Cortical areas of variant Creutzfeldt-Jakob disease (CJD; n = 3), young sporadic CJD (n = 4), different Gerstmann-Sträussler-Scheinker's disease patients (n = 5) and AD cases (n = 5) were examined using immunohistochemistry and specific stainings for amyloid.
RESULTS: In both AD and prion disease cases, which were negative for 4-kDa β-amyloid, parenchymal and vascular amyloid deposits were positive for amyloid-associated proteins such as complement protein and were associated with microglia clusters. Tau and ubiquitin were found near prion plaques in some of the Gerstmann-Sträussler-Scheinker's disease and sporadic CJD cases and also near vascular prion amyloid deposits. In variant CJD cases, occasionally, microglia clustering was found in plaques but no ubiquitin or complement proteins and hardly tau protein.
CONCLUSIONS: In both AD and prion disease amyloid formation, irrespective of the protein involved, there seems to be a neuroinflammatory response with secondary neurofibrillary degeneration.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22398730     DOI: 10.1159/000335380

Source DB:  PubMed          Journal:  Neurodegener Dis        ISSN: 1660-2854            Impact factor:   2.977


  7 in total

1.  A roadmap for investigating the role of the prion protein in depression associated with neurodegenerative disease.

Authors:  Danielle Beckman; Rafael Linden
Journal:  Prion       Date:  2016-03-03       Impact factor: 3.931

2.  Megalencephalic Leukoencephalopathy with Subcortical Cysts Protein-1 (MLC1) Counteracts Astrocyte Activation in Response to Inflammatory Signals.

Authors:  Maria Stefania Brignone; Angela Lanciotti; Barbara Serafini; Cinzia Mallozzi; Marco Sbriccoli; Caterina Veroni; Paola Molinari; Xabier Elorza-Vidal; Tamara Corinna Petrucci; Raul Estévez; Elena Ambrosini
Journal:  Mol Neurobiol       Date:  2019-06-17       Impact factor: 5.590

3.  Celecoxib Inhibits Prion Protein 90-231-Mediated Pro-inflammatory Responses in Microglial Cells.

Authors:  Valentina Villa; Stefano Thellung; Alessandro Corsaro; Federica Novelli; Bruno Tasso; Luca Colucci-D'Amato; Elena Gatta; Michele Tonelli; Tullio Florio
Journal:  Mol Neurobiol       Date:  2014-11-18       Impact factor: 5.590

Review 4.  Molecular basis of etiological implications in Alzheimer's disease: focus on neuroinflammation.

Authors:  Rituraj Niranjan
Journal:  Mol Neurobiol       Date:  2013-02-19       Impact factor: 5.590

5.  Role of nuclear receptor on regulation of BDNF and neuroinflammation in hippocampus of β-amyloid animal model of Alzheimer's disease.

Authors:  Atish Prakash; Anil Kumar
Journal:  Neurotox Res       Date:  2013-11-26       Impact factor: 3.911

6.  Oridonin attenuates Aβ1-42-induced neuroinflammation and inhibits NF-κB pathway.

Authors:  Sulei Wang; Hui Yang; Linjie Yu; Jiali Jin; Lai Qian; Hui Zhao; Yun Xu; Xiaolei Zhu
Journal:  PLoS One       Date:  2014-08-14       Impact factor: 3.240

7.  Label-free vibrational imaging of different Aβ plaque types in Alzheimer's disease reveals sequential events in plaque development.

Authors:  Dominik Röhr; Baayla D C Boon; Martin Schuler; Kristin Kremer; Jeroen J M Hoozemans; Femke H Bouwman; Samir F El-Mashtoly; Andreas Nabers; Frederik Großerueschkamp; Annemieke J M Rozemuller; Klaus Gerwert
Journal:  Acta Neuropathol Commun       Date:  2020-12-11       Impact factor: 7.801

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.